Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $110
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $63 to $110.
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $63 to $110.